Right Ventricle Lipid in Pulmonary Arterial Hypertension (PAH)

Part of paid clinical trials in Nashville, Tennessee.

Sponsor
Vanderbilt University Medical Center
Study ID
NCT05462574
Status
Recruiting
Apply to this trial

Conditions

  • Heritable Pulmonary Arterial Hypertension
  • Idiopathic Pulmonary Arterial Hypertension
  • Pulmonary Arterial Hypertension Associated With Connective Tissue Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • No Intervention — OTHER
    No Intervention

Study Details

The investigators propose to study the relationship between right ventricle (RV) steatosis and RV function, exercise capacity, and outcomes in humans with pulmonary arterial hypertension (PAH) and to identify potential drivers of lipid accumulation.

Key Dates

Start date
Jan 17, 2023
Status verified
May 2026
Primary completion
Sep 30, 2027
Completion
Sep 30, 2027

Study Design

Enrollment
75 participants (estimated)

Arms

  • Arm: Participants with Pulmonary Arterial Hypertension (PAH)
    Participants with heritable, idiopathic, and scleroderma associated PAH.

Primary Outcome Measure

Change in Right Ventricular (RV) Ejection Fraction [ Time Frame: Baseline to 36 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Vanderbilt University Medical CenterNashvilleTennessee37232-

Find similar trials in Nashville, TN

By research site
Vanderbilt University Medical Center· Nashville, TN

Related Studies